



Pharmacyclics

Pharmacyclics, Inc. 995 E. Arques Avenue Sunnyvale, CA 94085-4521 408.774.0330 ◆ 408.774.0340 Fax www.pcyc.com

FAX RECEIVED

DEC 0 c 2002

GROUP 1600

Facsimile Transmittal

To:

Examiner David Lukton

Patent Examiner, Group 1800

From:

Vinit Kathardekar

Pharmacyclics, Inc.

Tel:

703.308_3213

Tel.:

1.408.774.0330

Fax:

703.872.9306

Fax:

1.408.774.0340

Date:

December 5, 2002

CC:

Pages (including this cover sheet):

If there are any transmission problems, please call Rhonda Stine at 408.215.3429.

Re:

U.S. Patent Application No. 09/699,027

Filed: 10/27/2000

Response to Restriction Requirement


Docket No.: 4202.01 US

THIS FACSIMILE MESSAGE IS INTENDED ONLY FOR THE INDIVIDUAL OR ENTITY TO WHICH IT IS ADDRESSED. It may contain privileged, confidential attorney work product, or trade secret information that is exempt from disclosure under applicable laws. If you are NOT the intended recipient, you are hereby notified that any dissemination, distribution, copying, or the taking of any action in reliance on the contents of this message is strictly prohibited. If you have received this message in error, please notify us immediately by telephone and return the original message (and all copies) to us by mail to: Pharmacyclics, Inc., 995 E. Arques Avenue, Sunnyvale, CA 94085, Tel 408.774.0330, Fax 408.774.0340. Thank you.

TRANSMITTAL LETTER (General - Patent Pending)				Docket No. 4202.01 US	
In Re Application Of:					
Jonathan L. Sessler et al.					
Serial No.	Filing Date	E	xaminer	Group Art Unit	
09/699,027	10/27/2000	Lul	kton, David	1653	
Title: METHODS AND COMPOSITIONS FOR TREATING ATHEROMA, TUMORS, AND OTHER NEOPLASTIC TISSUE					
TO THE ASSISTANT COMMISSIONER FOR PATENTS:					
Transmitted herewith is:					
(1) Facsimile Cover Sheet; (2) Transmittal Letter; (3) Response to Restriction Requirement mailed 11/12/02; and (4) Certificate of Facsimile Transmission.					
in the above identified application. No additional fee is required. A check in the amount of is attached. The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 16-1450 as described below. A duplicate copy of this sheet is enclosed. Charge the amount of Credit any overpayment. Charge any additional fee required.					
Dated: December 5, 2002 Vinit G. Kathardekar, Reg. No. 39,461					
Pharmacyclics, Inc.				ment and fee is being faxed 5, 2002	
Sunnyvale, CA 94085 Phone: 408.774.0330			under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C.		
Fax: 408.774.0340					
Email: Legal@pcyc.com	•		Signature of Pers	on Faxing Correspondence	
				T 9	
cc:			Typed or Printed Name	OF Person Faving Correspondence	

4087740240

CERTIFICATE OF TRANSMISSION BY FACSIMILE (37 CFR 1.8) Docket No.						
Applicant(s): Jonathan L	. Sessier et al.		4202.01 US			
Serial No. 09/699,027	Filing Date 10/27/2000	Examiner Lukton, David	Group Art Unit 1653			
Invention:						
METHODS AND COMPOSITIONS FOR TREATING ATHEROMA, TUMORS						
AND OTHER NEOPLASTIC TISSUE						
\$						
•						
I hereby certify that this						
I hereby certify that this	 -	(Identify type of correspondence)				
is being facsimile transm	nitted to the United States Paten	t and Trademark Office (Fax. N	10. 703.872.9300			
on December 5	5, 2002					
(Date)			•			
		Rhonda J.	Stine			
		(Typed or Printed Name of Person	on Signing Certificate)			
Rhends O Strine (Signature)						
		(digmuure	<i>,</i>			
			/			
	Notes Each namer must h	ave its own certificate of mailing.				
	110te: Each paper mass.					
]						
1			•			



CERTIFICATE OF MAILING

I hereby certify that these papers are being sent by facsimile to the United States Patent and Trademark Office addressed to Examiner David Lukton, Patent Examiner, Group 1800, of the Assistant Commissioner Patents, Washington D.C. 20231, on:

Khenda Q Rhonda J. Stine Date: December 5, 2002

4 9 12/1/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Jonathan L. Sessler et al.

Attorney Docket No.:

4202.01 US

Serial No.:

09/699,027

Group Art Unit:

1653

Filed:

October 27, 2000

For:

METHODS AND COMPOSITIONS FOR TREATING ATHEROMA, TUMORS

AND OTHER NEOPLASTIC TISSUE

RESPONSE AND ELECTION

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

In response to the Restriction Requirement mailed November 12, 2002, Applicants hereby respectfully elect Group 6 (claims 20-24) with traverse. Applicants further acknowledge the Examiner's position that one or more of the non-elected groups could be rejoined if claims within Group 6 are found allowable without significant (further) limitation.

In the interest of having the instant case prosecuted, Applicants elect the following species:

- Motexafin Gadolinium (MGd) as the agent that accumulates in neoplastic tissue (a) in accordance with Claim 20, step (a);
- Ascorbate as the cellular metabolite in accordance with Claim 20, step (a); **(b)**
- Ascorbate as the "cellular metabolite" in accordance with Claim 20, step (c); (c)
- (ii) lonizing radiation is not required required. (d)